G1 Therapeutics, a commercial-stage oncology company, is inviting investors and industry professionals to join a webcast and conference call on May 1, 2024. The event will provide a financial and corporate update for the first quarter of 2024. To register for the event and receive the necessary dial-in information, interested individuals can follow the provided link on the company’s website. It is recommended to join the event 10 minutes prior to the start time. A live and archived webcast will be available on the Events & Presentations page of the company’s website for those who are unable to attend the live event.
G1 Therapeutics, Inc., headquartered in Research Triangle Park, N.C., is a commercial-stage oncology biopharmaceutical company dedicated to developing and delivering next-generation therapies that improve the lives of individuals impacted by cancer. The company’s first commercial product is COSELA® (trilaciclib), which has been approved by regulatory agencies in several countries for use in combination with chemotherapy for breast cancer patients with high risk of recurrence. Additionally, G1 Therapeutics is evaluating therapies in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs such as triple-negative breast cancer and extensive stage small cell lung cancer.
To learn more about G1 Therapeutics or their products, visit their website at http://www.g1therapeutics.com or follow them on social media platforms like X (formerly known as Twitter) @G1Therapeutics or LinkedIn. For any further information or inquiries, individuals can contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com
